Please assess the completion status of the following clinical trial:

Trial Title: Strategies in Patients Undergoing Repeat AF Ablation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: All patients undergoing first redo AF ablation who have chronically isolated pulmonary veins and no non-PV triggers with provocation testing (randomized intra-procedure).~Exclusion Criteria:~1. Patients in whom ≥1 PVs have reconnected and AF triggers can be elicited from the reconnected PV.~2. Patients who demonstrated non-PV triggers for AF.~3. Patients who have experienced arrhythmia recurrence post ablation where the recurrent arrhythmia is other than atrial fibrillation or typical atrial flutter~4. Failure to obtain informed consent~5. Patients with a mechanical mitral valve

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CTI/AAD (control) (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 1- Cavo-tricuspid isthmus (CTI) ablation with adjustment and/or optimization of antiarrhythmic drug regimen where possible (control arm)
- Posterior wall isolation (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 2-LA Posterior wall isolation by creation of a LA roof and floor line
- Empiric Isolation of common trigger sites (Type: EXPERIMENTAL): In all arms, patients are undergoing first redo AF ablation and the pulmonary veins are chronically isolated and no non-PV triggers elicited during provocation. Arm 3-empiric ablation of common sites of non-PV triggers of AF in both the right and left atria.

Based on this trial design, predict the completion outcome and termination type (if applicable).